Shared from parkinsonsnewstoday.com.
Irlab Therapeutics has announced new advancements for its three symptoms-targeting Parkinson’s disease drugs — medications designed to treat apathy, prevent falls, and reduce uncontrolled movements, known as dyskinesia, among people with the neurodegenerative disease.
Before the year’s end, the company intends to launch a Phase 1b clinical trial testing its IRL757 oral tablets for treating apathy, or a loss of motivation, in people with Parkinson’s. Irlab has received $4 million in funding from a partner for this study, the company stated in its latest interim report, covering the period from January through September.
The developer also shared new data showing that pirepemat, its oral medication for preventing falls in people with Parkinson’s, was shown to significantly reduce fall risk after three months in a clinical trial.